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The Illness Management and Recovery (IMR) program
was developed based on a comprehensive review of research
on teaching illness self-management strategies to clients
with schizophrenia and other severe mental illnesses and
‘‘packaged’’ in a resource kit to facilitate dissemination.
Despite growing dissemination of this program, it has
not yet been empirically validated. This article describes
the development and theoretical underpinnings of the
IMR program and presents pilot data from the United
States and Australia (N = 24, 88% schizophrenia or schiz-
oaffective) on the effects of individual-based and group-
based treatment over the 9-month program and over a
3-month follow-up. High satisfaction was reported by
participants. Strong improvements over treatment and at
follow-up were found in clients’ self-reported effectiveness
in coping with symptoms and clinicians’ reports of global
functioning and moderate improvements in knowledge
about mental illness, distress related to symptoms, hope,
and goal orientation. These findings support the feasibility
and promise of the IMR program and point to the need for
controlled research to rigorously evaluate its effects.
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The past decade has witnessed an unparalleled focus on
quality improvement in services for schizophrenia and
other severe mental illnesses. Much of this focus has
been stimulated by the identification of standards for
care for schizophrenia based on research evidence,1 cou-
pled with the finding that these practices were rarely pro-
vided.2–4 The President’s New Freedom Commission5
drew attention to the disparity between research and
practice and called for a transformation of the mental
health system to one that provides access to high-quality
treatment based on the best scientific evidence and
embraces clients and their families as partners in treat-
ment. In addition, the report echoed the growing consen-
sus that treatment should focus on not just managing
symptoms but on recovery, which was defined as helping
people with mental illness ‘‘live, work, learn, and partic-
ipate fully in their communities.’’
Traditional medical definitions of recovery focus on re-
mission of symptoms and return to prior functioning. Al-
though medical recovery from schizophrenia occurs,6–11
alternative definitions have emerged that are more per-
sonal in nature and emphasize a blend of subjective
aspects with improved functioning.12–16 These personal
conceptualizations evoke several common themes, in-
cluding hope, social connection, personal responsibility,
meaningful life activities, a positive identity, full life
beyond the illness, and personal growth.14,16–20
Recovery or living successfully with any chronic health
condition requires individuals to learn how to manage
their illness in collaboration with treatment providers.21
In the broader health field, evidence supports the value
of teaching illness self-management for improving
chronic medical conditions such as diabetes, arthritis,
and asthma.22 In addition, collaborative management
of chronic illness, which involves the patient and doctor
working together to identify problems, set goals, incorpo-
rate self-management strategies, and monitor progress
over time,23 leads to higher levels of trust and satis-
faction, reduced emotional burden, and improved bio-
medical markers such as blood pressure and blood
sugar control (eg, hemoglobin A1Cs).
24 However, the
vast majority of people with schizophrenia still need
help managing their illness, collaborating with treatment
providers, and pursuing their recovery goals.
Relapses of psychotic symptoms are common and
have a disruptive effect on the quality of clients’
lives and their capacity for independence.25–27 Although
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new antipsychotics continue to be developed, persistent
psychotic symptoms plague 25%–50% of clients with
schizophrenia,28–32 and these symptoms are associated
with a host of negative outcomes, including depression
and demoralization,33–36 impaired social functioning,37,38
and low employment.39,40 Over 85% of persons with
schizophrenia are unemployed,41 despite the fact that
most want to work42–45 and are capable of working in
competitive jobs.46 Furthermore, although most clients
live in the community, many lead lonely, isolated lives,
without social or recreational outlets or personal
purpose.47–50
In addition, there is a lack of active collaboration be-
tween people with schizophrenia and their treatment pro-
viders. Treatment plans often fail to address clients’
goals, and clinicians assume that they need to be pro-
tected from stress and live in protected settings,47 despite
evidence to the contrary.50 Pharmacological treatment is
often provided with little explanation or choice,51 thereby
compromising adherence52 and increasing risk of relapse.
There is a need for interventions that teach clients how to
manage their schizophrenia collaboratively with treat-
ment providers, in order to help them improve their lives.
Illness Management and Recovery Program
The Illness Management and Recovery (IMR) program
was developed in order to help clients with schizophrenia
or major mood disorders learn how to manage their ill-
nesses more effectively in the context of pursuing their
personal goals.53 The impetus for developing IMR ini-
tially arose at a Robert Wood Johnson Foundation Con-
sensus conference of National Institute of Mental Health
staff, services researchers, advocates, and the schizophre-
nia Patient Outcomes Research Team1,2 in Baltimore in
1997, where it was suggested that the various psychoso-
cial interventions for helping people manage their symp-
toms and prevent relapses needed to be consolidated into
a single standardized program for study and dissemina-
tion. To meet this need, the IMR program was developed
as part of the National Implementing Evidence-Based
Practices (EBPs) Project54–56 between 2000 and 2002
and packaged as an ‘‘implementation resource kit’’
designed to foster its dissemination (eg, manual and
handouts, information brochures, introductory and
training videos, fidelity scale, outcome measures). All
of the EBP resource kits were developed by 2 coleaders
and a committee of stakeholders, including researchers,
clinicians, consumers, family members, and program
leaders. Susan Gingerich and Kim Mueser were the
coleaders for the IMR resource kit.
The IMR program was developed based on a review of
controlled research on teaching illness self-management
strategies to clients with severe mental illness.57 Five em-
pirically supported strategies were identified in this re-
view and incorporated into the program, including
psychoeducation about mental illness and its treatment,
cognitive-behavioral approaches to medication adherence
(eg, incorporating cues for taking medication into daily
routines), developing a relapse prevention plan, strength-
ening social support by social skills training, and coping
skills training for the management of persistent symp-
toms. In order to motivate clients to learn how to better
manage their illness and to help them move forward in
their lives, IMR begins with an exploration of the mean-
ing of recovery to the client and setting personal recovery
goals to work toward in the program.
The five empirically supported illness self-management
strategies are incorporated into the IMR program, which
is organized into 9 curriculum topic areas. These topics
are taught using a combination of educational, motiva-
tional, and cognitive-behavioral teaching strategies,
with weekly individual or group sessions requiring ap-
proximately 9 months to complete. Homework assign-
ments are developed collaboratively with the client. In
addition, with clients’ consent, significant others (eg,
family, friends) are encouraged to be involved in helping
clients learn self-management strategies and pursue their
personal goals. All the materials for the IMR program
(except the videos, available by writing Substance Abuse
and Mental Health Services Administration [SAMHSA])
are available free from the SAMHSA Web site: http://www.
mentalhealth.samhsa.gov/cmhs/communitysupport/toolkits.
An outline of the curriculum taught in IMR is provided
in table 1.
Theoretical Underpinnings of IMR. The IMR program
integrates specific empirically supported strategies for
teaching illness self-management into a cohesive treat-
ment package based on 2 theoretical models: the trans-
theoretical model and the stress-vulnerability model.
The transtheoretical model proposes that motivation
to change develops over a series of stages (precontempla-
tion, contemplation, preparation, action, maintenance)
and that facilitating change requires stage-specific inter-
ventions.58,59 At the earliest stages, people are not com-
mitted to change and intervention focuses on instilling
motivation. In the IMR program, motivational inter-
viewing60,61 is used at the beginning and throughout
the program to help clients develop their own vision of
recovery, to identify and pursue their personal goals
based on that vision, and to explore how improved illness
management can help them achieve these goals.
The stress-vulnerability model62,63 posits that the
course and outcome of schizophrenia is determined by
the dynamic interplay of biological vulnerability, stress,
and coping. IMR is aimed at interrupting the cycle of
stress and vulnerability that leads to relapse and poor
functioning (see figure 1). In IMR, the proximal goal is
to teach clients the fundamentals of illness self-management
based on the stress-vulnerability model (ie, adherence to
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Table 1. Overview of Topics for Illness Management and Recovery (IMR) Modules
Module Topic Goals Number of Sessions
1 Recovery strategies d Engage clients in group
d Increase awareness of recovery 4
d Set personal recovery goals
d Develop plans for achieving goals
2 Practical facts about schizophrenia d Identify symptoms associated with
schizophrenia
d Dispel myths about schizophrenia
d Address stigma
d Help clients become aware of
people with schizophrenia who lead
productive lives
4
3 Stress-vulnerability model and treatment
strategies
d Explain that stress and biological
vulnerability cause symptoms of
schizophrenia
d Discuss strategies for reducing stress and
biological vulnerability
d Inform clients about treatment
options
3
4 Building social support d Discuss how building social support can
facilitate recovery
d Teach strategies for increasing support,
such as finding places to meet people,
conversation skills, and getting closer
to people
7
5 Using medications effectively d Teach clients about benefits and side
effects of medications
d Increase skills for discussing medication
issues with physician
d Help clients weigh pros and cons of
taking medications
d Teach behavioral tailoring to facilitate
medication adherence
4
6 Reducing relapses d Teach clients that relapses are
predictable and preventable
d Develop an individual relapse
prevention plan
4
7 Coping with stress d Inform clients they can reduce stress
and improve their ability to cope with it
effectively
d Identify and practice strategies to prevent
and to cope with stress
5
8 Coping with problems and persistent
symptoms
d Teach problem-solving model
d Help clients identify common
problems and symptoms that
cause distress
d Practice coping strategies for persistent
symptoms
6
9 Getting your needs met in the mental health
system
d Review different mental health services
d Identify insurance benefits clients are
entitled to
d Help clients identify strategies to
advocate for self in mental health system
3
Note: Since the completion of this study, a 10th IMR module has been developed for Drug and Alcohol Use that is usually taught
between the fifth and sixth modules. This module provides information on the effects of substance use on mental illness, reasons for
using the pros and cons of continued use vs sobriety, and (for motivated clients) developing a personal sobriety plan. The handout for
this module and clinical guidelines for teaching it can be obtained from Dr Mueser.
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medications, reduced substance use, increased social sup-
port, increased coping, involvement in meaningful activ-
ities) in order to improve illness outcomes such as
symptoms, relapses, and hospitalizations. Then, through
the combination of pursuing personal goals and im-
proved illness self-management, the distal goal of IMR
is to help clients make progress toward recovery, includ-
ing objective (eg, community functioning, social relation-
ships, work) and subjective (eg, sense of purpose, hope,
confidence) dimensions.
Need for Research on the IMR Program. The standard-
ization of the IMR program, the free and easy access to
the resource kit, and its broadly accepted status as an
‘‘EBP’’ have led to its rapid adoption throughout the
United States since it became available in 2003. For ex-
ample, approximately 1700 IMR resource kits have been
distributed by SAMHSA (N. Brown, personal communi-
cation, February 2006), and an unknown number more
downloaded from SAMHSA’s Web site. Furthermore,
the IMR program has become the focus of federal grants
aimed at dissemination, developing reimbursement pol-
icies to support its implementation, or adapting it for
special populations (C. Boyle and M. P. Salyers, unpub-
lished data, 2006, SM56140:10/03–09/06; J. M. J. Marti-
nez, unpublished data, 2006; E. G. Riera, unpublished
data, 2006, R34MH074786:10/05–09/08; M. P. Salyers,
unpublished data, 2006, H133G030106:10/03–09/06; G.
C. Souther, unpublished data, 2006, 11-P-92508/1:10/04–
19/07; T. White, unpublished data, 2006).
Despite the growing popularity of the IMR program, it
has not yet been critically evaluated. Furthermore, al-
though IMR incorporates specific empirically supported
strategies for teaching illness self-management, its em-
phasis on developing and pursuing personal recovery
goals is unique. Research is needed to determine whether
the IMR program in fact improves the management of
severe mental illness and longer term functional out-
comes such as community adjustment and quality of so-
cial relationships. The present report provides pilot data
on the effects of the IMR program, implemented in
a number of different formats (individual and group)
in several different settings.
Methods
The study took place at 3 different centers, 2 in North
Carolina (NC) and 1 in Australia, and employed either
individual or group formats.
Study Sites and Participants
In NC, individual IMR was provided at the Schizophre-
nia Treatment and Evaluation Program at the University
of NC at Chapel Hill (N = 13) and group IMR was con-
ducted at the Wake County Human Services in Raleigh,
NC (N = 9). Inclusion criteria were ages 18–65 and State
Fig. 1. Conceptual Framework for the Illness Management and Recovery program.
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of NC designation of severe mental illness (Axis I disorder
and impaired social, vocational, or self-care functioning).
There were no exclusion criteria.
In Australia, group IMR was implemented at the
Newcastle Community Mental Health Service (N = 10).
Inclusion criteria were ages 18–65 and a diagnosis of
schizophrenia or schizoaffective disorder.
All participants were assessed at baseline, posttreat-
ment, and 3-month follow-up.
IMR Program Implementation: All Sites
IMR was introduced to clients at all sites with an orien-
tation videotape, which describes the program and fea-
tures clients telling their recovery stories. Each IMR
module includes an educational handout that summa-
rizes the main points of the topic and worksheets to en-
hance learning. Clinicians used a variety of techniques to
optimize learning and retention, such as interactive teach-
ing and checking for understanding during each session.
Sessions were held weekly over approximately 9 months
and comprised 9 modules taught sequentially. Each mod-
ule lasted approximately 2–4 weeks but varied depending
on clients’ abilities and preferences.
Individual and group IMR sessions followed a stan-
dardized structure53:
1. Informal socializing. The clinician and clients used
this time to build rapport and discuss any additional
issues that needed to be covered at the end of the session.
2. Review content from previous sessions. Material was
reviewed from the previous session in order to assess
clients’ understanding and retention of information
and skills.
3. Review home assignment from previous session. Com-
pletion of home assignments was reviewed, successful
efforts by clients or outcomes were reinforced, and any
difficulties encountered were collaboratively problem
solved by the clinician and clients.
4. Follow up on goals. Clients’ progress toward their per-
sonal goals was assessed, obstacles were identified and
problem solved together, and success was followed up
by determining and planning the next steps or setting
new goals.
5. Set agenda for current session. An agenda was collab-
oratively set for the remainder of the session.
6. Teach new material and practice new strategies. Mate-
rial in the handouts for the IMR program was
reviewed and taught using a combination of educa-
tional, motivational, and cognitive-behavioral strate-
gies, tailored to each consumer’s reading ability,
interests, previous knowledge, and goals.
7. Collaboratively formulate home assignment for the next
week. Clinicians and clients agreed on a home assign-
ment to review and practice material taught in the ses-
sion or to make steps toward clients’ personal goals,
anticipated any obstacles that might prevent comple-
tion of the assignment, and problem solved ways to
overcome those obstacles.
8. Summarize progress made in current session. Material
covered in session was reviewed and feedback
obtained from the clients.
Individual IMR—United States
The individual IMR therapists included 2 clinical psy-
chologists, a clinical psychology graduate student, and
2 psychiatry residents. All the therapists received weekly
individual supervision from one of the authors (Dr Penn).
Sessions lasted approximately 1 hour.
Group IMR—United States
The IMR group was coled by a clinical psychologist
(Dr Penn), a psychiatrist, and a licensed social worker,
and sessions lasted about an hour. The group leader
role was rotated, with the 2 other mental health profes-
sionals serving as coleaders and facilitators. In addition
to clients in the group having home assignments, similar
assignments were also developed for the group leaders in
order to improve group cohesion and provide role mod-
els. The IMR material was reviewed using PowerPoint
in half the sessions, depending on the availability of
the liquid-crystal display (LCD) projector, giving the
group a classroom feel. In the other sessions, the material
was reviewed on paper.
Group IMR—Australia
All clinicians (N = 25) working at the Newcastle Mental
Health Service attended a 2-day IMR training program.
Even though clinicians were trained in the IMR program
and introduced to the concepts of evidence-based tool-
kits, most were skeptical and remained unenthusiastic
regarding the introduction of the program. However,
clinicians involved in delivering the IMR groups were
drawn from staff who were committed to the program’s
implementation. The initial group was led by a clinical
nurse consultant and cofacilitated by a senior social
worker. The second group was led by a senior social
worker and cofacilitated by a registered nurse.
The Australian IMR groups were conducted using
comparable methods to those employed in the United
States. There were some differences in session duration;
in Australia, each session consisted of two 45-minute
meetings with a 30-minute break in between. The IMR
modules were converted to PowerPoint to assist in the
group-based delivery of the program. The visual impact
of the modules combined with pictures was useful for cli-
ents who responded better to visual rather than auditory
learning. The use of PowerPoint and LCD projector in
the group context not only provided an excellent medium
to deliver the program but also afforded the opportunity
for group facilitators to model completion of worksheets
while the electronic image was being projected onto
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a whiteboard. The clients responded very positively to
these changes and stated that they felt like they were
attending a class rather than a ‘‘group.’’
The original modules received from the United States
were reformatted using larger font sizes and line spacing,
specific language changes were made as needed, and the
module on ‘‘Getting Your Needs Met in the Mental
Health System’’ was changed to incorporate the services
specific to the Australian context. Each module was
printed on colored paper, with a different color for
each module. This increased the visual appeal of the mod-
ules and assisted less literate participants within the
groups. Additionally, the group developed home assign-
ment cards that were small enough to fit in a wallet or
purse to help improve follow-through.
Regular supervision sessions ensured faithful adher-
ence to the group structure and core IMR strategies
described in the IMR toolkit and outlined previously.
Measures
Self-report measures were given to clients to assess
several domains of illness management and recovery.
Illness Management. The Brief Symptom Inventory
(BSI)64 is a 53-item scale used to evaluate psychiatric
symptoms with an global composite score (global severity
index [GSI]), which was developed based on the longer
Symptom Checklist-90, Revised (SCL-90).65 Each item
is measured using a 5-point distress scale that ranges
from 0 (not at all) to 4 (extremely). The SCL-90 and
BSI were designed to measure symptom distress related
to 9 different subscales, with coefficient a values for the
subscales on the BSI ranging from .63 to .89 in clients
with either depression or schizophrenia,66 indicating
good internal reliability. Factor analyses of the SCL-90
and BSI suggest they measure a single factor related to
distress.66,67 Convergent validity of the BSI in schizo-
phrenia68 is supported by significant associations with
quality of well-being69 and self-reported health and men-
tal health functioning on the Medical Outcomes Study
36-item Short Form Health Survey.70
The Coping Skills Scale was adapted from a coping
measure developed by Mueser et al.71 Coping strategies
and their perceived efficacy were elicited in a semistruc-
tured interview for up to 15 distressing symptoms. There
are no psychometric data on this scale from prior studies.
For the present study, coefficient a was .74 for ratings of
coping effectiveness, indicating good internal reliability;
convergent validity was supported by a Pearson correla-
tion of .66 between number of distressing symptoms and
BSI GSI score.
The IMR Scale72 taps all the critical self-management
domains targeted in the IMR program and uses 5-point
behaviorally anchored scales. In this pilot study, we used
a shortened version of the Client IMR Scale with 11 items
that included progress toward goals, knowledge about
mental illness, involvement with significant others and
self-help, time in structured roles, impairment in func-
tioning, symptom distress and coping, relapse prevention
and hospitalizations. Prior research on the Client IMR
Scale indicates satisfactory internal reliability (coefficient
a = .70), test-retest reliability over 2 weeks (r = .82), and
convergent validity with the Recovery Assessment Scale
(RAS)73 and the Colorado Symptom Inventory74 (r val-
ues = .38 and .54, respectively). The Knowledge Ques-
tionnaire is a 42-item multiple-choice and true/false
test designed for the IMR program to assess knowledge
of mental illness. Psychometric data on this scale are not
available from prior research; for the present study, co-
efficient awas .59, indicating moderate internal reliability.
Recovery. The RAS73 is a 41-item scale used to assess
perceptions of recovery from severe mental illness with
a 5-point Likert scale. The RAS includes 5 factors: per-
sonal confidence and hope (eg, ‘‘Fear doesn’t stop me
from living the way I want to’’), willingness to ask for
help (eg, ‘‘I ask for help when I need it’’), goal and success
oriented (eg, ‘‘I have goals in my life that I want to
reach’’), positive reliance on others (eg, ‘‘I have people
I can count on’’), and not dominated by symptoms
(eg, ‘‘My symptoms interfere less and less with my
life’’). Prior research on the RAS indicates high internal
reliability (coefficient a = .93), test-retest reliability over
2 weeks (r = .88), and convergent validity with the
Rosenberg Self-Esteem Scale,75 the Empowerment
Scale,76 the Social Support Questionnaire,77 the subjec-
tive component of the Quality of Life Interview,78 and
the Brief Psychiatric Rating Scale79 (r values = .55,
.71, .48, .62, and .44, respectively).80
The Multidimensional Scale of Perceived Social Sup-
port (MSPSS)81 is a self-report inventory that measures
perceived social support from family, friends, and a signif-
icant other. The MSPSS consists of 12 items that assess
the degree of satisfaction with social support. Prior re-
search on the MSPSS indicates high internal reliability
(coefficient a values = .91 and .94 for schizophrenia
and major mood disorders, respectively) and moderate
convergent validity with the Network Orientation Scale82
(r = .31). The original MSPSS used a 7-point Likert scale
that ranges from 1 (very strongly disagree) to 7 (very
strongly agree); however, due to a word-processing error
in this study, a 4-point scale was used. The items were
then summed as an overall measure of social support.
The Global Assessment of Functioning (GAF) scale83
was used as a measure of psychological, social, and oc-
cupational functioning with ratings ranging from 1 to
100. The GAF has well-established reliability, even for
minimally trained raters, and abundant evidence sup-
ports its validity.84,85 Lastly, each participant was asked
to complete a 6-item satisfaction survey. Each item had 3
choices (not helpful, helpful, or very helpful).
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Data Analytic Plan
All analyses were performed using SPSS. Participants
who completed at least baseline and posttreatment
assessments were included in the final analysis. We
compared the dropouts with the participants who com-
pleted the study using t test and v2 analyses. We also com-
pared the US and Australian clients on all demographic
and clinical measures to determine if there were any
differences between the groups.
To compare the IMR treatment effects over time on
measures of symptoms, recovery, and functioning, linear
mixed-effects regression models were computed with un-
structured and first-order autoregressive covariance ma-
trixes using the MIXED procedure. Time and treatment
group were used as fixed effects, and random intercepts
were allowed for each participant. After conducting
a global F test, pairwise comparisons of adjusted means
between all time points were conducted using 2-tailed
Tukey tests for each measure. Effect size estimates were
calculated by using Cohen’s d statistic for paired t tests
from baseline to follow-up, and missing data was replaced
using the Last Observation Carried Forward method. To
assess satisfaction with IMR treatment, frequencies from
the satisfaction survey were reported.
Results
Of the 12 individuals who were recruited into the US in-
dividual IMR treatment program, 10 completed the treat-
ment and 2 dropped out. The length of treatment ranged
from 3.23 to 9.23 months with a mean of 6.59 (SD = 1.96)
months. The mean length of time between the posttreat-
ment and follow-up assessment was 3.77 (SD = 0.98)
months. In the US IMR group, 9 individuals were
recruited into the study and 8 completed at least half
the sessions and were included in this pilot study. Six par-
ticipants completed the entire protocol, one left the group
after the first month, one left midtreatment to return to
school, and one stopped attending after 6 months. The
dropouts were compared with the participants who com-
pleted the treatment on demographic characteristics and
the baseline measures, and no differences were found.
The IMR group lasted for 9.46 months, and the mean
length of time between the posttreatment and follow-
up assessment was 5.31 (SD = 0.42) months.
In Australia, 10 individuals were recruited into 2 IMR
groups with 6 out of 10 participants completing the entire
program over the 2 groups. Retention rates in the first
Australian IMR group were low. Four out of 5 clients
dropped out; 1 client left the group after 2 sessions, an-
other client chose to leave the group after 5 sessions, and
2 moved away from the area after completing 6 and 11
sessions, respectively. One participant completed the
program in 8.54 months, and the length of time between
the posttreatment and follow-up assessments was 3.46
months.
Retention rate for the second Australian IMR group
was significantly better with 5 out of 5 clients completing
the entire program. This group lasted for 9.92 months,
and the length of time between posttreatment and
follow-up assessment was 3 months. Possible reasons
for the improved retention are considered in the ‘‘Discus-
sion’’ section.
The US and Australian participants did not signifi-
cantly differ on any demographic or functioning varia-
bles, including age, education, race, diagnosis, gender,
or GAF, and thus, the sites were combined for all further
analysis.
Table 2 shows the demographic and clinical character-
istics of the combined sample. The majority of the sample
was Caucasian, male, and never married. Most partici-
pants had a diagnosis of either schizophrenia or schizo-
affective disorder.
After IMR treatment, participants showed improve-
ments in illness management and recovery domains
(see table 3). Clients reported significant decreases in
symptom severity from baseline to follow-up. Addition-
ally, clients reported some improvements in effective cop-
ing strategies for their symptoms as measured by the
Coping Skills Scale from baseline to posttreatment but
not at follow-up. Illness self-management was enhanced
as shown by increases in IMR Scale scores from baseline
to posttest. Participants also improved in their knowl-
edge of mental illness at posttreatment and follow-up.
Recovery attitudes also showed a pattern of improve-
ment at posttreatment. Scores on the RAS suggested that
Table 2. Demographics Total Australian/US Sample (N = 24)
Mean (count) SD (%)
Age 39.12 11.20













Schizoaffective disorder 11 46
Bipolar disorder 2 8
Delusional disorder 1 4
Treatment
Individual IMR 10 42
Group IMR 14 58
Note: IMR, Illness Management and Recovery.
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participants had more hope about recovery and felt less
dominated by their symptoms. These improvements were
maintained through follow-up. GAF scores improved
significantly from baseline to posttest and were sustained
over follow-up. Perceived social support did not change
over time.
Additional analyses were conducted to evaluate differ-
ences between clients in the individual and group IMR
formats over time. Only one significant difference
emerged: individual participants had higher scores across
all 3 time points on the relying on others subscale of the
RAS than the group participants (individual M = 17.63,
SD = 0.51; group M = 16.01, SD = 0.47; F1,23 = 5.43,
P = .03).
Results from the satisfaction survey are summarized in
table 4 and indicated that most participants found the in-
tervention to be helpful, respectful, and useful.
Discussion
The pilot data on the implementation of the IMR program
supports both its feasibility and its acceptability. The rates
of program retention, defined as participation in more
than half of the IMR sessions, were high for both group
and individual IMR at the NC sites, with 19 out of 22
(86%) clients ‘‘treatment takers.’’ Retention rates were
low in the first group conducted at the Australia site
(20%) but high in the second group (100%). Possible







M SD M SD M SD F (df) P d
Illness management
BSI GSIa 1.03 0.17 0.92 0.15 0.77 0.14 4.37 (2, 22) .03 .50
Coping—total symptomsb 6.05 1.07 4.62 0.95 5.87 1.18 2.28 (2, 14) .14 .38
Coping effectivec 3.05 0.28 3.55 0.27 3.25 0.21 3.79 (2, 22) .04 .84
Client IMR—shortened/sumc,d 36.97 2.29 45.82 2.18 42.08 2.62 10.82 (2, 16) .00 .83
Knowledge of illnessd,e 91.52 1.38 95.32 0.86 94.66 1.34 6.63 (2, 23) .01 .63
Social support 45.82 1.96 47.65 1.64 46.90 1.88 0.44 (2, 20) .65 .18
Recovery
Recovery meand,e 3.81 0.10 3.98 0.10 4.04 0.11 4.76 (2, 41) .01 .64
RAS—hoped,e 32.75 1.14 34.27 1.14 34.96 1.19 3.66 (2, 40) .04 .55
RAS—willingness ask help 12.11 0.32 12.91 0.32 12.73 0.36 2.71 (2, 40) .08 .30
RAS—goal orientedd,e 18.75 0.84 20.17 0.84 20.94 0.91 3.28 (2, 39) .05 .48
RAS—rely on others 16.90 0.41 16.53 0.41 17.03 0.44 1.24 (2, 41) .30 .02
RAS—not dominated symptomd,e 9.95 0.54 11.24 0.54 11.48 0.60 3.48 (2, 41) .04 .60
GAFd,e 53.71 2.43 61.45 3.05 59.99 3.43 10.91 (2, 18) .00 .80
Note: IMR, Illness Management and Recovery; BSI, Brief Symptom Inventory; GSI, global severity index, GAF, Global Assessment of
Functioning.
aBaseline > follow-up (P < .05).
bN = 16.
cN = 15.
dBaseline < posttest (P < .05).
eBaseline < follow-up (P < .05).







Covers sufficient material 1 (4) 21 (96) 0
Materials are understandablea 1 (5) 10 (48) 10 (48)
Useful 0 13 (59) 9 (41)
Respectful 0 9 (41) 13 (59)
Helps better manage symptoms 0 15 (68) 7 (32)
Helps recovery 0 14 (64) 8 (36)
aN = 21.
S39
Illness Management and Recovery Program
reasons for the high dropout rate in the first Australian
IMR group may be related to the Australian services’ ini-
tial low readiness to embrace EBPs in the toolkit form
at the time of recruitment for the this group. Higher reten-
tion of participants in the second Australian group may
have been due to a combination of factors, including im-
proved support from case managers for clients’ attendance
at the groups, increased acceptance of the IMR program
by clinicians, and referral of clients to IMR who were more
stable in terms of symptoms and living situation.
Clients who participated in IMR expressed high satis-
faction, with all reporting that the program was useful, re-
spectful, helpful for managing their symptoms, and helped
them make progress toward their goals. All but one client
found the program covered sufficient breadth of informa-
tion and that the materials were understandable. While
dropouts were probably less satisfied with the program,
these findings suggest that most found the materials
and approach helpful to managing their illness and mak-
ing progress toward personally meaningful goals.
Changes from baseline to posttreatment and follow-up
indicated significant effects across most measures, with
no interactions between treatment modality (individual
vs group) and change over time. The largest effect sizes
were for clients’ ratings of their coping effectiveness (d =
.84), the Client IMR Scale (d = .83), and GAF score (d =
.80). These findings are in line with the primary aims of
the IMR program. Skills for coping with persistent symp-
toms are systematically taught, and clients reported bet-
ter coping self-efficacy for these symptoms. This is
consistent with studies showing that the number of cop-
ing strategies clients report using to manage symptoms is
correlated with their coping efficacy71,86,87 and with re-
search on the effects of teaching coping strategies for per-
sistent symptoms.88 The IMR Scale was developed in
order to tap the specific dimensions of illness self-
management targeted in the IMR program (eg, progress
toward goals, support in managing one’s illness, use of
medication adherence strategies, involvement in struc-
tured activities, having a relapse prevention plan), and
thus, improvements in it are in line with the aims of
the program. Of greatest significance was the finding
that participation in IMR was associated with improve-
ments in functioning on the GAF. These findings are also
consistent with the main goal of the IMR program, which
is to help clients articulate personally meaningful goals
and to learn how to manage their illness in the service
of making progress toward these goals.
Moderate effect sizes were also found for several other
outcomes. Consistent with improvement in coping self-
efficacy, clients also reported modest improvements in
distress related to their symptoms on the BSI (d = .5). Fur-
thermore, in line with the aim of the IMR program of pro-
viding clients with information about mental illness and its
treatment in order to facilitate informed decision making,
significant improvements were found in knowledge of the
illness (d = .63). Finally, clients who participated in the
IMR program showed significant improvements in
hope (d = .55) and goal orientation (d = .48) on the
RAS. The importance of hope to recovery has been em-
phasized by many people with mental illness.19,27,89 The
increased orientation toward goals on the RAS may be re-
lated to the focus of IMR on helping clients articulate and
make progress toward personal goals and on removing ill-
ness-related obstacles to achieving them.
The effect sizes were small and nonsignificant for
improvements in social support and help from others.
Willingness to ask for help on the RAS showed a modest
improvement (d = .30), while satisfaction with social sup-
port showed a small but nonsignificant improvement (d =
.18) and reliance on others on the RAS showed no change
at all (d = .02). The relative lack of change in support has
several possible interpretations and implications. First,
improvements in the quality of social relationships and
social support may simply take longer to accrue. For ex-
ample, skills training programs usually report changes in
social functioning in schizophrenia over 1–2 years.90,91
Thus, improved illness self-management, including skills
for developing closer relationships with others, could
lead to gradual improvements in social support over
the longer term. Second, the relatively small amount of
time devoted in the IMR program to improving social
support (1 out of 9 modules) may be insufficient to
make an impact on social relationships. Social skills
training has the best track record for improving social
functioning in schizophrenia,92 with programs usually in-
volving a minimum of 3–6 months of concerted skills
training, considerably more than is provided in IMR.
Third, it is possible that more could be done in the
IMR program to help clients collaborate actively with
significant others in learning how to manage their psychi-
atric illness. Although collaboration with significant
others is identified as a core feature of IMR,53 anecdotal
reports indicate that such collaboration occurs in only
a minority of clients who participate in the program. Be-
cause social contact with others and social support are
established predictors of the course of schizophrenia93–95
and family psychoeducation reduces relapses and reho-
spitalizations,96 developing additional strategies in the
IMR program to foster collaboration with significant
others is an important priority.
One possible strategy is to formally incorporate into
training programs for IMR clinicians skills for collabo-
rating with families (and other significant persons).
Another strategy would be to offer a regular multifamily
psychoeducational group (eg, monthly), with topics
based on the IMR curriculum, for participants in the
IMR program and their significant others. This group
could provide an opportunity to review the fundamentals
of illness management with concerned others in a context
where clients could get support and help in pursuing their
personal recovery goals.
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In summary, these pilot data support the feasibility of
implementing the IMR program for clients with schizo-
phrenia receiving services at typical community mental
health center settings and suggest that participation in
the program is associated with benefits in illness manage-
ment, progress toward recovery, and improved function-
ing. These findings suggest that controlled research is the
next step toward evaluating the effects of the IMR pro-
gram. Such research might be undertaken with several
considerations in mind. First, assessments should focus
on both traditional domains of illness management,
such as symptoms and rehospitalizations, and outcomes
related to both the subjective and objective aspects of re-
covery, such as community functioning, social relation-
ships, personal empowerment, and sense of purpose.
Qualitative assessments of the experience of recovery
would be an additional welcome feature that could illu-
minate the process of growing ‘‘beyond the catastrophic
effects of mental illness.’’12 Second, as the IMR program
is aimed at helping clients develop skills for managing
their illness and pursuing personal goals, follow-up
assessments are needed to determine whether gains con-
tinue to accrue after the program has ended, such as 9–12
months later. Third, given that one of the main goals of
IMR is to reduce relapses and associated acute care serv-
ices, attention to the effects of the program on reducing
the costs associated with such services would be of
interest.
Several limitations of this study should be noted. Al-
though experienced clinicians provided IMR services
to the individuals and groups in these settings, the
IMR program was new to these clinicians, and the
data reported here are from those early treatment expe-
riences. With more practice and experience with the IMR
model, it is plausible that clinicians would become more
effective and would improve treatment retention and out-
comes. The sample was predominantly Caucasian, indi-
cating that work is needed on more racially-ethnically
diverse populations. In addition, ratings of clients’ func-
tioning were not obtained by blinded interviews, but
rather by clinicians who were familiar with the clients,
and may have been biased in their ratings of improve-
ment. These limitations notwithstanding, the present
study provides a basis for cautious optimism that the
marriage between focusing on recovery and learning to
manage one’s psychiatric illness may be a fruitful ap-
proach to empowering clients to take control over their
illness and achieving personally important goals.
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